Jack C. Stromatt
Jack C. Stromatt
Verified email at
Cited by
Cited by
BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
DR Buelow, B Bhatnagar, SJ Orwick, JY Jeon, ED Eisenmann, ...
Blood advances 6 (17), 5049-5060, 2022
TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
ED Eisenmann, JC Stromatt, S Fobare, KM Huang, DR Buelow, S Orwick, ...
Cancers 15 (1), 29, 2022
High-Dimensional Analysis Identifies Mechanisms of Gilteritinib Resistance in FLT3-Mutated AML
DR Buelow, B Bhatnagar, JY Jeon, MZ Thomas, E Eisenmann, J Stromatt, ...
Blood 138, 207, 2021
Preclinical Characterization of TP‐0903, a Novel Multikinase Inhibitor, in TP53 Mutant Acute Myeloid Leukemia
E Eisenmann, S Fobare, K Huang, JY Jeon, R Weber, J Silvaroli, ...
The FASEB Journal 35, 2021
Characterizing Imatinibˇ¦s Pharmacokinetics and Impact on Neuronal p-ERK Signaling
S Kandalai, J Stromatt, E Ahmed, N Halloy, L Steenrod, J Hoak, ...
Journal of Pharmacology and Experimental Therapeutics 389 (S3), 2024
Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)
D Buelow, X Yang, D Nicolet, K Mrózek, K Krowiorz, R Bhayadia, ...
Blood 142 (Supplement 1), 4126-4126, 2023
Characterization of microenvironmental-mediated gilteritinib resistance in Acute Myeloid Leukemia using a Bmx knockout mouse model
JC Stromatt, DR Buelow, SJ Orwick, E Eisenmann, NS Pabla, BW Blaser, ...
Journal of Pharmacology and Experimental Therapeutics 385 (S3), 2023
The system can't perform the operation now. Try again later.
Articles 1–7